Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03881735
Title Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Roswell Park Cancer Institute
Indications

acute myeloid leukemia

Therapies

Enasidenib

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST